All In Biotech

Drug Trial Radar · NCT05702229

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

163

Planned (sponsor's estimate)

Start

Jan 16, 2023

Primary completion

Nov 30, 2027

Study completion May 31, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Conditions

  • Gastric Cancer

Interventions

  • RilvegostomigDrug

    an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion

  • VolrustomigDrug

    an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion

  • FOLFOXDrug

    5-fluorouracil oxaliplatin, leucovorin (levoleucovorin when locally preferred and available)

  • XELOXDrug

    capecitabine and oxaliplatin

  • AZD0901Drug

    an anti Claudin18.2 ADC; IV infusion

  • 5-FluorouracilDrug

    5-FU, IV infusion

  • CapecitabineDrug

    Oral take

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR (per RECIST 1.1 as assessed by Investigator)Time frame: Through substudy completion, an average of 2 years
  2. PFS6 (per RECIST 1.1 as assessed by Investigator)Time frame: Through substudy completion, an average of 2 years

Locations

44 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Los Angeles, California · Withdrawn

  • Research Site

    Baton Rouge, Louisiana · Recruiting

  • Research Site

    Grand Rapids, Michigan · Recruiting

  • Research Site

    New Hyde Park, New York · Withdrawn

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    Shirley, New York · Withdrawn

  • Research Site

    The Bronx, New York · Withdrawn

  • Research Site

    Pittsburgh, Pennsylvania · Withdrawn

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Hangzhou, China · Recruiting

  • Research Site

    Hangzhou, China · Recruiting

  • Research Site

    Harbin, China · Recruiting

  • Research Site

    Hefei, China · Recruiting

  • Research Site

    Kunming, China · Completed

  • Research Site

    Wuhan, China · Recruiting

  • Research Site

    Yinchuan, China · Recruiting

  • Research Site

    Zhengzhou, China · Recruiting

  • Research Site

    Chūōku, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Sunto-gun, Japan · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Barcelona, Spain · Recruiting

  • Research Site

    Elche(Alicante), Spain · Recruiting

  • Research Site

    L'Hospitalet de Llobregat, Spain · Recruiting

  • Research Site

    Madrid, Spain · Recruiting

  • Research Site

    Madrid, Spain · Recruiting

  • Research Site

    Santander, Spain · Recruiting

  • Research Site

    Hsinchu, Taiwan · Recruiting

  • Research Site

    Kaohsiung City, Taiwan · Recruiting

  • Research Site

    Taichung, Taiwan · Recruiting

  • Research Site

    Tainan, Taiwan · Recruiting

  • Research Site

    Taipei, Taiwan · Recruiting

  • Research Site

    Taipei, Taiwan · Recruiting

  • Research Site

    Taoyuan, Taiwan · Recruiting

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.